The Pharma Letter Podcast — Episode 27 — How to develop cancer drugs faster, with Ellipses Pharma

This week we are speaking with the chief executive of British drug development company Ellipses Pharma. 

Founded in 2018 to create new cancer therapies, the firm is following a unique multimodal approach to clinical development, leveraging a variety of technologies.

That’s not the only way that Ellipses is rethinking drug development. The company uses a consultative model to provide an unbiased vetting process for candidates, with the goal of de-risking initial asset selection.

Ellipses also wants to make sure that capital is invested in the most efficient way, pursuing a portfolio-based strategy which ensures uninterrupted development capital for each asset.

Our guest on the show is Ellipses CEO and co-founder, Dr Rajan Jethwa.